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Germline CYLD mutation is associated with the development of a rare inheritable syndrome, called the CYLD
cutaneous syndrome. Patients with this syndrome are distinctly presented with multiple tumors in the head and
neck region, which can grow in size and number over time. Some of these benign head and neck tumors can turn
into malignancies in some individuals. CYLD has been identified to be the only tumor suppressor gene reported to
be associated with this syndrome thus far. Here, we summarize all reported CYLD germline mutations associated
with this syndrome, as well as the reported paired somatic CYLD mutations of the developed tumors. Interestingly,
whole-exome sequencing (WES) studies of multiple cancer types also revealed CYLD mutations in many human
malignancies, including head and neck cancers and several epithelial cancers. Currently, the role of CYLD mutations
in head and neck carcinogenesis and other cancers is poorly defined. We hope that this timely review of recent
findings on CYLD genetics and animal models for oncogenesis can provide important insights into the mechanism
of head and neck tumorigenesis.
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Understanding of genetic diseases that are closely linked to
tumor development can provide important insights into the
biology of human tumorigenesis and treatment. To date,
only a handful of human genetic diseases are uniquely asso-
ciated with predisposition of head and neck tumor forma-
tion. In this focused review, we will provide an up-to-date
summary of the cylindromatosis (CYLD) gene defects in a
genetic disease called the CYLD cutaneous syndrome. This
genetic syndrome is, in particular, characterized by multiple
tumor formation in the head and neck region often with
early age onset. Some of these tumors will remain benign,
while some can turn malignant. Interestingly, CYLD genetic
aberrations have recently been reported by recent whole-
exome sequencing (WES) studies in head and neck cancers,
and some other cancers, thus revealing its potential in-
volvement in human carcinogenesis. Therefore, it is timely
to review the genomic aberrations of CYLD in this particu-
lar genetic disease, which will deepen our understanding of
human tumorigenesis, in particular, of the head and neck.
The CYLD gene
The CYLD gene (chr 16q12.1) codes for a 107 kDa cyto-
plasmic deubiquitinating (DUB) enzyme, which removes
ubiquitin molecules from various signaling proteins, and
regulates the activities of many cellular and signaling pro-
cesses. This gene was first discovered and cloned in 2000
by Bignell et al. with prior evidence suggesting the exist-
ence of a potential tumor suppressor gene on chr 16q12-
q13 linked to a peculiar cutaneous disease characterized
by multiple tumors in the head and neck region [1]. Sub-
sequent functional studies revealed multiple roles of CYLD
in the regulation of inflammation, immunity, cell cycle pro-
gression, spermatogenesis, osteoclastogenesis, ciliogenesis,
migration and potentially tumorigenesis [1–4]. To date,
several major signaling pathways have been found to be
linked with or regulated by CYLD, which include the
Nuclear Factor-kB (NF-kB), Wnt/β-catenin and c-Jun
NH(2)-terminal kinase (JNK) pathways, and potentially
others [5–7]. Genetic alterations of CYLD could result in
aberrant activation or inhibition of these signaling path-
ways, which may contribute to disease pathology.
The CYLD cutaneous syndrome
In 1842, a rare cutaneous disease was first described in a
female patient, named Frances Massenger, who developedmultiple tumors in the head, neck and face. In addition to
her early disease onset at age 14, multiple family members
of this patient also had a history of head and neck tumors
[8], which strongly implied a potential underlying genetic
cause of this rare disease. Over a century later in 1995,
Biggs et al. discovered the locus of the susceptibility gene
on chromosome 16q12-q13 by linkage analysis of the
members of two affected families, revealing the potential
loss of a likely tumor suppressive gene associated with this
rare syndrome [9]. The following year, Biggs et al. pro-
vided further evidence to suggest that CYLD (referred to
as Cyld1) may be the only tumor suppressor gene involved
in the CYLD cutaneous syndrome [10]. A subsequent lar-
ger study with 21 affected families ultimately helped to
identify the gene associated with this syndrome to be the
CYLD gene on chromosome 16q12 and detected, for the
first time, germline and somatic mutations of CYLD in af-
fected patients [1]. The gene was cloned by fine-mapping
and positional cloning and it was confirmed that CYLD
germline mutations are associated with and are the under-
lying cause of this cutaneous syndrome in humans [1].
The term, CYLD cutaneous syndrome, was proposed
recently by Rajan et al. [11] to describe this rare inherit-
able condition that is known to be caused by germline
mutations of the CYLD gene based on genetic evidence
[9]. The occurrence rate of CYLD germline defects is
~1:100,000 based on the UK data [12]. Patients with this
syndrome are clinically characterized with multiple tu-
mors of the skin appendages often in the head and neck
region (i.e. skin lesions derived from the epidermal ap-
pendages, hair follicles, sweat apparatus, etc.). The CYLD
syndrome encompasses three previously known appen-
dageal tumor predisposition syndromes: familial cylin-
dromatosis (FC, or Turban tumor syndrome; OMIM
132700), multiple familial trichoepithelioma 1 (MFT1;
also called epithelioma adenoides cysticum, EAC, or
Brooke-Fordyce trichoepitheliomas; OMIM 601606), and
Brooke-Spiegler syndrome (BSS or BRSS; OMIM
605041), which are believed to be allelic disorders with
overlapping phenotypes associated with CYLD muta-
tions. The clinical manifestations of these CYLD-associ-
ated syndromes as well as the images for the head and
neck, and facial manifestations have been recently
reviewed [13]. All three tumor predisposition syndromes
are autosomal dominant disorders, in which a germline
CYLD mutation was inherited, and a second, non-inherited
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cells for tumor formation. FC is typically presented with
multiple cylindromas (i.e. benign tumors with differenti-
ation towards apocrine sweat glands that increase in num-
ber and size over age). These multiple cylindromas growing
in the scalp may coalesce and cover the entire scalp like a
turban (thus FC is also called the Turban tumor syndrome).
MFT1 is characterized by multiple trichoepitheliomas (i.e.
skin tumors on the face with histologic dermal aggregates
of basaloid cells with connection to or differentiation to-
ward hair follicles), which can turn into basal cell carcin-
oma [14]. BSS, mostly with early adulthood onset, is
classically characterized by multiple skin appendage tumors
including cylindroma, trichoepithelioma, and spiradenoma
(eccrine spiradenomas or cystic epitheliomas of the sweat
gland, usually solitary, deep-seated dermal nodule typically
located in the head and neck region [15]). Since members
of a single family can manifest as FC, MFT1 or BSS with
CYLD aberrations, many consider these three diseases as a
phenotypic spectrum of a single disease entity with under-
lying CYLD mutation. These tumors can be painful, itchy
and irritating, and in some cases, turn to malignancies. Due
to the very disfiguring nature of these head and neck, facial
tumors, surgical removal and often repeated surgeries are
performed on these individuals to limit tumor growth over
their life-time. The psychological impacts due to the disfig-
uring appearance of affected individuals may lead to de-
pression and social withdrawal [16].
To date, the CYLD cutaneous syndrome has been re-
ported in various ethnic backgrounds, with age onset as
early as 5, to 40 years old. The average age onset is around
teenage (~16 years old) [11]. Such an early age onset of
multiple tumor formation distinctly in the head and neck
region strongly imply a potential critical role of CYLD mu-
tations in promoting head and neck tumorigenesis.
CYLD Germline and somatic mutations in individuals with
the CYLD cutaneous syndrome
As of today, a total of 107 germline CYLD mutations
have been reported in patients developing FC, BSS and
MFT1 (Table 1). Most reported mutations reside be-
tween exons 9 and 20 of the CYLD gene. The current
data revealed several hotspot mutation sites of CYLD:
1112C > A (S371*), 2272C > T (R758*) and 2806C > T
(R936*) in 14, 10 and 13 independent families, respect-
ively [17–19] (Fig. 1). Note that all three hotspot
mutations are nonsense mutations, which are likely to
produce truncated forms of the CYLD protein, poten-
tially representing loss-of-function of the CYLD protein.
In fact, the majority of CYLD germline mutations are
deleterious mutations, including frameshift (44 %),
splice-site (11 %), nonsense mutations (25 %), germline
deletions (2.7 %) followed by missense mutations (11 %)
and silent mutations (1 %) (Table 1). Note that a fewstudies reported the absence of detectable CYLD germ-
line mutation in a small number of affected individuals
[20, 21]. It is possible that some CYLD alterations may
have been missed as these previous studies examined
only certain exons/regions CYLD using direct sequen-
cing, or probe-based fluorescence in-situ hybridization
(FISH) or linkage analysis. Thus far, no single study has
sequenced the entire CYLD gene including the regula-
tory and intronic regions, which can also be potentially
altered but missed by targeted sequencing. Note that spor-
adic occurrences of the syndrome have also been reported.
In those cases, only the affected individual, but not their
family members, will carry a germline CYLD mutation
and present with the syndrome phenotype [22, 23].
Theoretically, it is possible that other genetic events, be-
sides CYLD, may be involved. Candidates like Patched 1
(PTCH1) has been proposed earlier, but later disputed to
be a potential candidate for the CYLD cutaneous syn-
drome [21, 24, 25]. As next-generation sequencing (NGS)
can now be easily employed to study various diseases, it is
likely that whole-exome or even whole-genome studies of
these head and neck tumors from affected individuals can
reveal previously unidentified genetic changes associated
with the disease, in addition to CYLD.
Patients with the CYLD cutaneous syndrome inherit
one copy of the mutated CYLD gene, while LOH or mu-
tation of the second copy of the CYLD gene occur som-
atically for tumor formation. Several studies investigated
the actual genetic change of CYLD in the developed tu-
mors versus that of the germline aberrations in affected
individuals. A total of 15 such cases have been reported
thus far. As shown in Table 2, tumors from each of the
15 cases all harbored additional CYLD aberration(s) dif-
ferent from the original germline CYLD mutation. In
some cases, somatic CYLD changes among different tu-
mors of the same individual can also be different. In
general, nonsense CYLD mutations seem to be the most
common germline event, while LOH or loss-of function
CYLD mutations (nonsense, or frameshift mutations)
were frequently detected as somatic events (Table 2).
This genetic pattern is supportive of the 2-hit hypothesis
of tumorigenesis, similar to that of the retinoblastoma 1
(RB1) gene alterations for the development of retino-
blastoma. Not only genetic heterogeneity was observed
among tumors from the same individual, the pathologies
of these tumors can also vary from benign to malignant
in some cases. It is likely that CYLD alteration is an early
event for head and neck tumorigenesis, and potentially
supportive of later malignant transformation over time.
CYLD aberrations with benign tumor formation or
malignant transformation?
Most clinical reports on the CYLD cutaneous syndrome
indicate that the majority of tumors developed in the
Table 1 Germline CYLD mutations reported in patients with the CYLD cutaneous syndrome




5 561-562dupT Q188Sfs 1 [23]
9 1027dupA T343Nfs 1 [20]
9 1096_1097delCA Q366Tfs 2 [20, 81]
9 1112C > A S371a 14 [1, 17, 20, 21, 81–85]
9 1135G > T E379a 1 [86, 87]
10 1139-1148A > G splice site mutation 1 [20]
10 1178_1179delCA T393Rfs 1 [88]
10 1207C > T Q403a 1 [86, 87]
10 1364_1365delAA Q455Rfs 1 [89]
10 1392_1393dupT G465Wfs 1 [23]
10 1455 T > G Y485a 1 [90]
10 1455 T > A Y485a 2 [1, 20]
10 1462delA I488Sfs 1 [25]
10 1473C > T I491I unavailable [91]
10 1518 + 2 T > C splice site mutation 1 [92]
11 1569 T > G Y523a 1 [1]
11 1628del2 S543a 1 [81]
11 1681_1682del L561Sfs 1 [1]
11 1682 T > A L561a 1 [85]
11 1684 + 1G > A splice site mutation 2 [20, 93]
12 1758insGATA M587Dfs 2 [20, 82]
12 1758ins2 M587fs 1 [81]
12 1776delA G593Afs 1 [1]
12 1783C > T Q595a 1 [94]
12 1787G > A G596D 1 [95]
12 1821_1826 + 1del-insCT splice site mutation 1 [96]
12 1826 + 1G > A splice site mutation 1 [97]
12 1826 + 1G > T splice site mutation 2 [20, 21]
13 1830-1831insA F611Ifs 1 [1]
13 1843delT S615Lfs 1 [98]
13 1859_1860delTG V620fs 2 [1, 81]
13 1863insA L622Tfs 1 [81]
13 1893_1906delATATTATAGTGAAA E631Dfs 1 [23]
13 1925delC T642Kfs 1 [108]
13 1935dupT N646a 1 [1]
14 1950-2A > T splice site mutation 1 [23]
14 1950_1953-1delGATA splice site mutation 1 [23]
14 1961 T > A V654E 2 [26]
14 2012-2021del10 A671Dfs 1 [99]
14 2032G > T E678a unavailable [91]
15 2041 + 1G > T splice site 1 [100]
15 2042-1G > C splice site 1 [109]
15 2042A > G D681G 1 [86, 87]
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Table 1 Germline CYLD mutations reported in patients with the CYLD cutaneous syndrome (Continued)
15 2065_2066delCT L689Vfs 1 [85]
15 2068_2069delTTinsC F690Lfs 1 [85]
15 2070delT H691Ifs 1 [110]
15 2081delT L694a 1 [86, 87]
15 2104delA I702a 2 [20, 90]
15 2104_2105insA I702Nfs 1 [24]
15 2108G > A R703K 1 [111]
15 2108G > C R703T 2 [20, 90]
16 2116_2117insATTAG G706Dfs 1 [112]
16 2119C > T Q707a 3 [20, 90]
16 2128C > T Q710a 2 [25, 108]
16 2138delA Y713Sfs 1 [1]
16 2146C > A Q716K 1 [85]
16 2154insT M719Yfs 1 [81]
16 2155dupA M719Nfs 1 [20]
16 2170_2172insTC K724Ifs 3 [20, 90]
16 2172delA V725Lfs 3 [1, 15, 81]
16 2214delT F738Lfs 1 [81]
16 2240A > G E747G 2 [81, 101]
16 2240_2241delAG E747fs 1 [102]
17 2252delG C751Ffs 1 [103]
17 2255delT L752Rfs 1 [83]
17 2259dupT I754Yfs 2 [20, 21]
17 2272C > T R758a 10 [1, 18, 20, 21, 85, 104, 113]
17 2288_2289delTT F763a 1 [20]
17 2290_2294del K764Ifs 1 [81]
17 2291_2295delAACTA K764Ifs 2 [20]
17 2299A > T K767a 5 [20, 83, 90]
17 2305_2306insC I769Tfs 1 [1]
17 2305delA I769Ffs 4 [82]
17 2330_2331delTA I777Nfs 2 [20, 105]
17 2339 T > G L780a 2 [81, 82]
18 2350 + 5G > A Splice Site Mutation 2 [1, 85]
18 2355_2358delCAGA R786Sfs 1 [106]
18 2409C > G Y803a 1 [89]
18 2449delT C817Vfs 1 [114]
18 2460delC C820a 2 [1, 11]
18 2465insAACA T822Tfs 1 [107]
18 2467C > T Q823a 1 [1]
18 2469 + 26G > A splice site mutation 1 [99]
18 2469 + 1G > A splice site mutation 2 [1, 11]
19 2546G > A W849a 1 [86, 87]
19 2552_2553insA H851Qfs 1 [115]
19 2569C > T Q857a 1 [1]
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19 2602G > T E868a 2 [1, 116]
19 2613C > G H871Q# 2 [91, 117]
19 2641delG D881Tfs 1 [20]
19 2655G > A W885a 1 [85]
19 2662_2664delTTT F888del 1 [85]
19 2666A > T D889V 1 [96]
20 2687G > C G896A 1 [118]
20 2709dupT P904Sfs 1 [119]
20 2711C > T P904L 1 [83]
20 2712delT Q905Kfs 1 [96]
20 2713C > T Q905a 1 [20]
20 2729dupC E911Rfs 3 [20, 90]
20 2806C > T R936a 13 [1, 19, 20, 22, 26, 81,
82, 91, 120]
20 2814_2817delGCTT L939Vfs 3 [20, 90]
20 2822A > T D941V 1 [25]
- 2686 + 60_a3340del5632b germline deletion 1 [85]
- 34111_a297858del378779c germline deletion 1 [121]
- 914-6398_1769del13642ins20d germline deletion 1 [121]
A total of 107 germline mutations of CYLD have been reported in the literature thus far. This table summarizes the reported DNA changes, protein changes, frequency
and original report of 105 germline CYLD mutations. Two additional germline mutations of CYLD were originally reported as 1862 + 2 T > G (splice site mutation) [102]
and 2317G > A [122], however, the protein change cannot be interpreted by sequence analysis and are therefore not included in this table. Based on the nucleotide
sequences provided by the original articles, we predicted the mutational changes on the CYLD protein using the Integrated Genomic Viewer (IGV) software (Broad
Institute, USA) as italicized- based on the reference GenBank number NM_015247 for CYLD. Abbreviations: del deletion, ins insertion, dup duplicate, a = introduction of
stop codon. Notes: bLarge deletion (~5.3kB) in the catalytic domain UCH region of CYLD. cLarge deletion (~13.6kB) from intron 6 to exon 12 affecting the 3rd CAP
domain and beginning of the UCH domain, additionally, a 20 bp insertion was detected. dLarge deletion (0.4 MB) of entire CYLD gene and some surrounding regions
Fig. 1 Reported CYLD germline mutations in patients with the CYLD cutaneous syndrome [1, 11, 17, 19–23, 25, 26, 81, 120]. The frequency of
familial cases of CYLD cutaneous syndrome with germline CYLD mutations, and the corresponding amino acid positions affected by these
mutations are indicated (as detailed in Table 1 and predicted using the Integrative Genomics Viewer (IGV) software, the Broad Institute, USA). The
CYLD protein contains three CAP-GLY domains (aa 155–198, 253–286, 492–535), a UCH catalytic domain (aa 591–950) and a Zinc binding region
(aa 778–842) within in the catalytic domain based on the NCBI number NP_056062.1
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Table 2 Reported paired germline and somatic CYLD mutations in patients with the CYLD cutaneous syndrome
Age of onset,
Gender
Severity Germline Mutation Somatic Mutation Malignancy Sequencing method and reference
DNA Protein DNA Protein












PCR. Sequenced CYLD coding regions
(exons 4–20) and splice sites.
GenBank#:NT010498.15 [110]
24, F S-VS 2806C > T R936c T1 n.s., n.s. R936c, D889N Benign PCR. All CYLD exons [22]
teens, F S 2012-2021del 10,
2469 + 26G > A
A671fs,
splice site mutation
T1 LOH - BCC PCR. Sequenced CYLD coding regions
and splice sites. GenBank#: NT010505.
Tumor LOH analysis using markers:
D16S3044, D16S308, D16S503 [99]
n.s., M Md 2104_2105insA I702fs T1 2541G > A W847c Benign PCR. Sequenced CYLD coding regions
(exons 4–19) and splice site. GenBank#:
AJ250014. Tumor LOH analysis using
markers: D9S925, D9S171 & D9S169-
(chr.9p2), D9S15, D9S252, D9S303, and
D9S287 (chr.9q22.3) and D16S 769, D16S
753, CDRP 28, CDRP 23, D16S 416, D16S
771, D16S 673 (chr.16) [24]
n.s., F
(Family1 mother)









n.s. Sequenced CYLD coding and non-coding
regions (exons 1–20) were analyzed.
GenBank#:AC007728. Tumor LOH analysis
using markers: D16S304, D16S308, D16S419,


















S 2104delA I702c T1 1112C > A S371c n.s.
n.s., F
(Family2 daughter)
Md-S 2104delA I702c T1 2467C > T Q823c n.s.
















46, F Md 2170_2171insTC K724Ifs T1 2046_2047ins AGATCCG E683Rfs n.s.
































Table 2 Reported paired germline and somatic CYLD mutations in patients with the CYLD cutaneous syndrome (Continued)
n.s., M Md-S 2814_2817delGCTT L939Vfs T1 LOH - n.s.



















Sequencing regions were not reported.
Tumor LOH analysis was performed
(markers not specified) [93]
The CYLD cutaneous syndrome patient cases reported with paired germline and somatic CYLD mutations; and including disease severity information and reported sequencing methods. Severity was defined as mild
(Md), severe (S) or very severe (VS) using the following criteria: Md = few, small tumors, not painful or overgrowing. S = Multiple large growths, painful/ulcerating and resulting in tumor excision. VS =Multiple large
tumors, often disfiguring, painful/ulcerating, resulting in multiple tumor excisions and/or complete scalp removal. Abbreviations: del deletion, ins insertion, dup duplicate, c = introduction of stop codon, BCC basal cell
carcinoma, LOH Loss of heterozygosity, n.s. not stated, CCD clear cell differentiation, T individual tumor used for analysis
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sive growth in size and number over one’s lifetime. How-
ever, emerging evidence is supportive of malignant
transformation of these usually benign tumors into ma-
lignancies in some affected individuals, perhaps even in
situ, arising from the original benign tumors [26]. In
fact, the very first case report of such cutaneous syn-
drome (though with unclear genetics), had extensively
documented multiple tumor formation in the patient's
peritoneum, reminiscent of the patient’s head and neck
tumors. The patient who later manifested a state of
cachexia did suggest a “malignancy” as indicated in the
report [8]. Yet, it remains unclear if these tumors in the
peritoneum were originated in situ or were actually
metastatic lesions from the head and neck tumors.
Due to the rarity of the syndrome, and repeated sur-
geries for most patients (for cosmetic reasons), docu-
mentation of malignant transformation of these
seemingly benign tumors is scarce. Recently, Kazakov
et al. reported multiple cases with histological evidences
suggesting that the malignant lesions seemed to develop
or transform in situ at the original “benign” tumors of
the cutaneous syndrome patients [26]. A histological
study showed that in an invasive carcinoma, the basal
cell adenocarcinoma (BCAC) of the salivary gland that
was developed in the affected individual, there remained
a residuum of spiradenoma which merged with the inva-
sive carcinoma by histology. Similar findings in another
affected individual showed that the benign tumor had
developed into an invasive lesion in the skull with a
BCAC histology. Invasive adenomas of various histolo-
gies have been identified in several affected individuals
as well. How did these malignant transformations occur
in situ? Did the tumors acquire additional genetic aber-
rations that caused or supported malignant transform-
ation? Or were the CYLD genetic aberrations (two
copies of CYLD mutated or loss) sufficient to drive such
a malignant transformation over time if the tumors had
not been excised early enough by surgery?
As demonstrated by chemically-induced colon and
liver cancer models with CYLD−/− mice [16, 27], it seems
that phenotypically invasive or potentially metastatic tu-
mors can develop with a CYLD deficient background
in vivo. This may imply that CYLD loss, together with a
strong cancer inducing agent or DNA mutagen, can turn
normal cells to tumors with the potential to further
transform into malignancies. This notion is further sup-
ported by findings from Alameda et al. that expression
of a catalytically inactive form of CYLD in a Ha-ras-mu-
tated tumorigenic epidermal cell line (PDVC57) signifi-
cantly promoted in vitro cell proliferation, migration
(with changes to a mesenchymal phenotype), anchorage-
independent growth, as well as pronounced in vivo
tumor growth and angiogenesis with upregulation ofvascular endothelial growth factor-A (VEGF-A) expres-
sion [28]. Using a subcutaneous tumor model, the au-
thors demonstrated that the CYLD mutant tumors not
only grew faster and larger in size, but also showed a
more aggressive, poorly differentiated phenotype when
compared to the control tumors which bore a less ag-
gressive, differentiated phenotype. It was hypothesized
that the presence of Ha-ras mutation in this cell model,
PDVC57, together with CYLD mutation, may be respon-
sible for such an aggressive phenotype, which is in con-
trast with the observed benign skin tumors developed in
CYLD−/− mice as previously reported by Massoumi et al.
[29]. These findings may suggest that CYLD may co-
operate with other oncogenic events, in this case Ha-ras
mutation, to promote malignant transformation. Thus,
future investigations on CYLD gene interaction may fur-
ther define the biological importance of CYLD in head
and neck carcinogenesis and progression.
CYLD Mutations in head and neck cancers, and other
human malignancies
CYLD has been suggested to be a tumor suppressor
gene, as supported by evidences from the first genetic
susceptibility study for the CYLD cutaneous syndrome
[1]. It is known that deleterious loss of an important
tumor suppressor gene in germline settings can confer
cancer predisposition in an inherited manner. A well-
known comparable example is the Li–Fraumeni syn-
drome, a rare cancer predisposition hereditary disease
caused by germline tumor protein 53 (TP53) mutations
and the affected individuals often develop various can-
cers at young age. Although our current understanding
of CYLD is insufficient, the very first reported case of
such a cutaneous syndrome in Frances Massenger
(1842) who first developed multiple scalp and face tu-
mors, and later, multiple abdominal/peritoneal tumors
reminiscent of the ones in her head and neck, and sub-
sequently died with symptoms of cancer cachexia did
suggest a potential link of the cutaneous syndrome to
malignant conditions [8]. Several female family members
also had a history of head and neck tumors (grand-
mother, mother, and sister), and breast tumors (sister),
suggesting the inheritable nature of the syndrome linked
to human malignancies. In fact, a recent study by
Kazakov et al. reported a total of 5 patients with BSS,
who were found to develop malignancies arising from
pre-existing tumors in the head and neck region [26].
Further microscopic analyses of the tumors confirmed
the presence of “residuum of a pre-existing benign neo-
plasm” indicative of in situ development of malignancies
from the apparently benign lesions. A handful of malig-
nant cases developed in patients with BSS have also been
reported by others [30–49]. These malignancies included
salivary gland type basal cell adenocarcinoma-like
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HG), invasive adenocarcinomas (IACs), squamous cell
carcinomas (SCCs), anaplastic neoplasms and sarcoma-
toid (metaplastic) carcinomas [34, 50–59].
Although it remains unclear how CYLD genomic aber-
rations precisely drive multiple head and neck tumor
formation, and potentially, malignant progression, CYLD
somatic mutations have been reported in a subset of
head and neck squamous cell carcinoma (HNSCC) pa-
tients as revealed by recent WES efforts of The Cancer
Genome Atlas (TCGA, USA). HNSCC is the most com-
mon type of head and neck cancer, ranking the sixth
most common cancer worldwide. A total of 8 CYLD
somatic mutations (8/279 patient cases) have been iden-
tified in primary HNSCC tumors by WES [60]. These in-
clude: F110L, V180Cfs*23, N300S, S361Lfs*47, S371*,
T575S, D618A, and K680*. Among which, the S371*
mutation has been found to be a hotspot germline muta-
tion in patients with the CYLD cutaneous syndrome as
mentioned above. Yet, the functional role of these CYLD
mutations in HNSCC development remains unknown.
Among the 8 CYLD-mutated HNSCC tumors, 4 were
Human Papilloma virus (HPV)-negative (all smokers;
age onset is 71.75 ± 3.77 years old) and the remaining 4
were HPV-positive (with 1 smoker only; age onset is
54.00 ± 6.82 years old). All HPV-negative CYLD-mutated
tumors were also TP53 mutated, while as expected, the
HPV-positive counterparts were all TP53 wildtype. Al-
though all patients carrying the CYLD-mutated HNSCC
tumors had advanced disease at the time of diagnosis
[Stage III (2/8 cases) and Stage IV (6/8 cases)], the pub-
lished TCGA cohort with only 8 CYLD-mutated cases
was not able to reveal any CYLD-mutation and overall
patient survival correlation (data not shown).
Besides the published HNSCC TCGA dataset, a recent
study has identified a high incidence of CYLD aberrations
in a rare salivary gland tumor, namely the dermal analogue
tumor, which can be of sporadic or familial origins. Der-
mal analogue tumor is a subtype of basal cell mono-
morphic adenoma with remarkable histological and
clinical resemblance to cylindromas. Choi et al. reported
that as high as 80.9 % (17/21) of the sporadic cases, and
75 % of familial cases (9/12 tumors from two sisters) har-
bored LOH near the CYLD gene locus (16q12-13) [51].
These findings suggest that both skin adnexal tumors,
which are commonly associated with the CYLD cutaneous
syndrome, and dermal analogue tumors may share a com-
mon genetic basis, namely CYLD genetic alteration.
Besides HNSCC, the TCGA WES efforts also revealed
other human cancers with a ≥3 % mutation rate of CYLD.
These include (arranged in descending order of percent
cases mutated in each cohort and the actual number
shown in the legend; Additional file 1: Figure S1): uterine
corpus endometrial carcinoma (5.2 %; 13/248 cases), lungsquamous cell carcinoma (4.5 %; 8/177 cases), stomach
adenocarcinoma (3.8 %; 15/395 cases) and lung adenocar-
cinoma (3 %; 7/230 cases). An additional 15 cancer types
harbor somatic CYLD mutations at ~1-3 % rates. These
are cancers of the skin, esophagus, colon, glioma, pan-
creas, liver and cervix, as well as intrahepatic cholangio-
carcinoma, small cell lung cancer, large B cell lymphoma,
thymoma, chromophobe renal cell carcinoma, multiple
myeloma, uveal melanoma, glioblastoma (TCGA, USA;
www.cbioportal.org; [61, 62]). Interestingly, two of the
germline CYLD hotspot mutations (S371* and R758*) in
CYLD cutaneous syndrome patients are also found in pri-
mary tumors of HNSCC, lung and stomach. Yet, the roles
of these CYLD mutations in these solid tumors remain
undetermined. It is possible that CYLD alterations may be
involved in the tumorigenesis of many other cancers, in
addition to head and neck cancers.
CYLD signaling
Important cellular processes are known to be regulated by
ubiquitination and deubiquitination of cellular proteins.
Ubiquitination of a protein can determine and regulate its
stability, and even its signaling functions [63]. Ubiquitins
(Ubs) are small proteins (8.5 kDa) with seven lysine (K)
residues (K6, K11, K27, K29, K33, K48 and K63). Ubiquiti-
nation of different K residues can serve different biological
functions. For instance, K48-linked ubiquitin chains on a
target protein directs the protein for proteosome degrad-
ation, while K63 links can promote protein-protein inter-
actions and signaling activation [2].
The CYLD protein has three cytoskeletal-associated
protein-glycine-conserved (CAP-GLY) domains and a
UCH catalytic domain with a zinc-motif [1] (Fig. 1). The
CAP-GLY domains combined with proline-rich regions
are responsible for microtubule and target protein bind-
ing, while the UCH domain mediates deubiquitination,
and the zinc-motif allows for CYLD folding and domain
interaction [1]. CYLD is highly specific for K63 ubiquitin
chains [64], however has also been demonstrated to me-
diate K48 deubiquitination of target proteins [65]. Target
proteins of CYLD include B-cell lymphoma 3 (Bcl-3),
Histone-deacetylase 6 (HDAC6), Transient receptor po-
tential cation channel A1 (TRPA1), NF-kB essential
modulator (NEMO), TRAF interacting protein (TRIP),
transforming growth factor-β-activated kinase 1 (TAK1),
receptor-interacting protein 1 (RIP1), retinoic acid-
inducible gene-1 (RIG1) and TNF-receptor associated
factor (TRAF) proteins, etc. [66]. Through deubiquitina-
tion of these signaling proteins, CYLD has been shown
to regulate major signaling pathways including the
NF-kappaB (NF-kB) (canonical and non-canonical),
Wnt/β-catenin and c-Jun NH(2)-terminal kinase (JNK)
pathways (Fig. 2) [5–7, 67]. Several studies showed that
the tumor suppressor CYLD inhibits NF-kB as well as
Fig. 2 CYLD-associated signaling pathways. NF-kB, Wnt/β-catenin, and JNK pathways have been shown to be regulated by CYLD. The canonical
NF-kB signaling pathway has been shown to be regulated by CYLD through deubiquitination of target substrates such as RIP1, the TAK1 complex
and NEMO [2]. In the non-canonical NF-kB signaling pathway, deubiquitination of Bcl-3 by CYLD results in the inhibition of cyclin D1 gene
expression [29]. Wnt/β-catenin signaling has been shown to be regulated by CYLD, via deubiquitination of the (disheveled) DVL protein [6]. The
JNK signaling pathway has been demonstrated to be regulated by CYLD activity through unknown mechanisms likely involving TRAF2 and MKK7
[7]. In addition, the Notch/Hes1 pathway and the Hedgehog signaling have been shown to regulate transcription of CYLD, via suppression of
CYLD transcription by Hes1 and snail1, respectively [69, 70]. Blue arrows indicate nuclear translocation of the proteins. The lower grey box shows
the published signaling changes and likely consequences of CYLD deficiencies due to CYLD knockout, CYLD silencing by siRNA or shRNA or CYLD
mutation. Red arrows indicate that the nuclear translocation of the indicated proteins was found to be increased. Potential therapeutic targets
due to CYLD aberrations are highlighted in red within the lower grey box
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several upstream regulatory signaling molecules of these
pathways, thus suppressing these signaling pathways
[68]. Alternatively, CYLD has been shown to be nega-
tively regulated by the Notch [69] and Sonic Hedgehog
(Shh) [70] signaling pathways in T-cell leukemia and
skin cancer, respectively (Fig. 2). As of today, among all
currently identified target proteins of CYLD, many are
signaling regulators of the NF-kB pathway (e.g. the
TRAF proteins, NEMO, TRIP, RIP1, TAK1 and Bcl-3).
Therefore, it is believed that genomic aberrations of
CYLD may alter NF-kB signaling activity, which may
also contribute to the pathophysiology of the CYLD cu-
taneous syndrome and tumor formation.
Although it is unclear if other non-NF-kB signaling
pathways are potentially involved, recent evidences re-
vealed such a possibility. CYLD has recently been shown
to promote ciliogenesis, a process that is plausibly asso-
ciated with tumorigenesis. The primary cilium is a cellsurface antenna-like structure sensing chemical and
mechanical signals from the environment on almost all
mammalian cells. Since the formation of the primary
cilium is coordinately regulated with the cell cycle pro-
gression via its connection with the centrosome, it has
been hypothesized that regulators of ciliogenesis may
also control cell proliferation and tissue homeostasis,
and defects in primary cilium formation or function may
contribute to tumorigenesis due to “non-communicative
and unrestrained growth” [71–73]. In fact, in addition to
this CYLD tumor suppressor, several key tumor suppres-
sors and oncogenes such as the VHL, PDGFR-α, and
Shh/Patched 1 (Shh/Ptch1) were recently identified to
regulate ciliogenesis [3, 4, 74]. Eguether et al. demon-
strated that both the centrosomal localization (via inter-
action with a centrosomal protein CAP350) and
deubiquitination activity of CYLD were required for its
ciliogenic activity, independent of NF-kB [3]. Note that
another NF-kB-independent and ciliogenic signaling
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ical signaling pathway regulating cell proliferation and
differentiation of basal cell carcinoma (a type of skin
cancer arising from epidermal stem cell of the hair folli-
cles) [75], has been recently identified as an upstream
regulator of CYLD expression (Fig. 2). It remains to be
investigated if this Shh/Ptch1-CYLD link is relevant for
ciliogenesis as well as tumorigenesis of the skin, which
can be pathologically related to this CYLD Cutaneous
syndrome.
CYLD and potential mechanisms of multiple head and
neck tumor development
Although the genetic link between CYLD defects and
the CYLD cutaneous syndrome has been identified, there
remain many interesting questions to be answered re-
garding this peculiar syndrome. How do CYLD germline
mutations give rise to “multiple” tumor formation, in
particular, in the head and neck region in these patients?
Furthermore, what are the molecular mechanisms
underlying the progression of benign tumor lesions to
malignancies in some patients?
Loss of CYLD links to multiple tumor development?
Almost all CYLD cutaneous syndrome patients do carry a
germline mutation of CYLD which is inheritable. Interest-
ingly, CYLD somatic mutations have also been identified
in sporadic cases of cylindroma [1] and spiradenoma pa-
tients [76]. This evidence suggests that CYLD aberration
is associated with the disease phenotype of multiple head
and neck tumors. Thus far, CYLD is the only tumor sup-
pressor gene identified to be linked with the disease.
Genetically-engineered mouse models have been gener-
ated to study the function of CYLD in mammalian set-
tings. A study by Massoumi et al. demonstrated that
CYLD knockout mice (with disruption of ATG start
codon) were much more susceptible to chemically-
induced cutaneous squamous papilloma formation upon a
single dose of 7,12-dimethybenza(a)anthracene (DMBA)
followed by 12-Otetradecanoylphorbol-13-acetate (TPA)
treatment [29]. All CYLD−/− mice developed skin tumors
(papillomas) after 11 weeks vs. only 50–60 % of tumor in-
cidence in CYLD+/+ mice at a later time of 16 weeks. Im-
portantly, mice with homozygous as well as heterozygous
loss of CYLD (i.e. CYLD−/− and CYLD+/− mice) both de-
veloped multiple tumor phenotype on the skin much earl-
ier than the CYLD+/+ mice. By week 16, CYLD−/− and
CYLD+/− mice harbored ~30 and 15 tumors/mouse, as
compared to only 5 tumors per mouse in the CYLD+/+
group. These results indicated that the loss of a single
copy of CYLD gene was sufficient to confer a “multiple
tumor phenotype” upon chemical insults in mice (al-
though the tumor-bearing phenotype is more severe when
both copies of CYLD were lost). Further, the averagetumor size of papilloma developed in the CYLD−/− mice
were >2.8 times of those found in the CYLD+/+ mice, im-
plicating a potential CYLD gene dose effect on tumor cell
proliferation. Despite the fact that spontaneous tumor de-
velopment was not observed in the CYLD−/− mice, loss of
CYLD (either one or both copies) did confer a “tumor sus-
ceptible phenotype” reminiscent of patients with the
CYLD cutaneous syndrome. It was further noted that the
tumor number and size in CYLD−/− and CYLD+/− mice
did grow over time after the initial DMBA/TPA insult,
which is also reminiscent of the tumor characteristics re-
ported in patients with the syndrome [1, 29]. Yet, all the
tumors developed in the CYLD−/− and CYLD+/− back-
grounds were hyperplastic lesions with no signs of malig-
nancy [29]. It is likely that the loss of this CYLD tumor
suppressor gene makes the entire epithelium of the skin
highly prone to tumor initiation by chemicals or environ-
mental insults in the “affected site”, skin in this model,
thus multiple tumors can develop in this “primed soil”.
This is further supported by another CYLD knockout
mice study, in which multiple tumors were developed in
the colon of the CYLD−/− mice in a chemical-induced
colitis-associated cancer (CAC) model [27], with which a
DNA mutagen (azoxymethane; AOM) and an
inflammation-inducing chemical (dextran sulphate so-
dium; DSS) were used in the drinking water to target the
colon epithelium of the animals. The study demon-
strated that as early as second round of DSS treatment,
the CYLD−/− mice developed multiple measurable
broad-based adenocarcinomas (i.e. flattened, or called
sessile) in the colonic epithelium, as compared to almost
no tumor in the CYLD+/+ mice. In humans, it is noted
that sessile polys or adenomas are pre-cancerous lesions
in the colon [77]. Further investigation demonstrated
that CYLD could limit inflammation and tumorigenesis
by regulating ubiquitination [27]. Similar multi-tumor
phenotype was also observed in a diethylnitrosamine
(DEN)-induced carcinogenic liver injury model, in which
significantly more, larger and multiple tumors with inva-
sive or metastatic potential (displaying trabecular sinus-
oidal structures related to initial stage of invasion and
metastasis in human hepatocellular carcinoma) were ob-
served in the livers of the CYLD−/− mice as compared to
that of the CYLD+/+ mice [68]. The observation that
multiple papillomas, colon adenocarcinomas, and liver
tumors were easily induced upon treatment with chem-
ical insults or DNA mutagens in CYLD knockout mice
did strongly imply a generalized tumor susceptibility na-
ture of the affected epithelium or tissue due to CYLD
mutation or CYLD loss. However, it remains unclear as
to why some tissues seem to develop potentially malig-
nant tumors (e.g. liver, and colon), while some tissues
tend to develop more benign tumors (e.g. skin papil-
loma) in vivo. Thus, it is important to determine if
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genic activity in various human cancer types.
Why do these tumors develop predominantly in the head
and neck region?
The next question is why these tumors mostly developed
in the head and neck, and face of the affected individ-
uals? The possible reason(s) may lie in the fact that these
areas are always exposed to strong chemical or DNA-
damaging insults. It is possible that frequent exposure to
UV, a strong DNA-damaging insult can serve as a tumor
inducer or potentiating agent for tumor development in
the epithelium of the head and neck, and the face. It has
been shown by Massoumi et al. that UV light could trig-
ger cellular proliferation of CYLD−/− keratinocytes, as
well as cyclin D1 expression [29]. The study proposed a
model that in the presence of UV light and in conjunc-
tion with CYLD loss, Bcl-3 will translocate into the nu-
cleus, complexed with p50 to induce cyclin D1
expression, thus cellular proliferation, while the presence
of intact CYLD will inhibit Bcl-3 nuclear translocation
and growth.
Another equally important possibility is the likely ori-
gin(s) of tumor from the hair stem cells as previously
suggested for cylindromas [78]. As the region of head
and neck, and the face harbor many stem cell -containing
hair follicles in the sebaceous and sweat glands, CYLD
genetic aberrations may affect the proliferation control, or
inflammatory status of the stem cell niches, thus resulting
in predominant head and neck tumor formation. Evidence
for this can be noted as these tumors never grow from the
hair-less parts of the body (e.g. the palms and soles), but
only in the hairy parts of the body. It is also possible that
hair follicle stem cells that harbor CYLD alterations may
acquire additional genetic changes over one’s lifetime thus
resulting in tumor formation. However, since the origin of
these tumors of the CYLD cutaneous syndrome patients is
still of debate, this hypothesis remains to be proven. An-
other possibility that remains to be proven is that, maybe,
CYLD is specifically and functionally associated with de-
velopmental control or growth regulation of the head and
neck or hair follicles in humans. Thus, germline defects of
CYLD in patients with the CYLD cutaneous syndrome are
mainly presented with head and neck tumors or tumors in
regions with lots of hair follicles.
As CYLD somatic mutations occur in HNSCC tu-
mors, and CYLD aberrations seem to be the key gen-
etic driver for multiple head and neck tumor
formation in patients with this cutaneous syndrome,
an unanswered question is whether CYLD aberration
alone is sufficient to directly drive head and neck
tumor formation. Do additional genetic or chemical
insults associated with head and neck carcinogenesis,
such as smoking, drinking, or HPV infection, promotetumorigenesis in CYLD-mutated head and neck can-
cers? Is the immune system involved as well, since
CYLD is also implicated in the regulation of immun-
ity? All these questions remain to be addressed.
Conclusions
The genetics of the CYLD cutaneous syndrome underlies
the formation of multiple tumors in the head and neck
epithelium. Current treatments are limited, except for
repeated surgical removal of the tumors when needed.
Inhibition of NF-kB signaling can potentially be a treat-
ment option. Yet, a prior clinical trial on the topical use
of salicylic acid showed some efficacies in some affected
individuals only (2/12 cases) [79]. A recent study showed
that CYLD mutations can cause activation of the tropo-
myosin kinase (TRK) signaling in tumors of affected in-
dividuals [80]. Further, inhibition of TRK signaling in
CYLD-mutant tumor models demonstrated the potential
efficacies of TRK targeting. Thus TRK inhibitors can be
a potential treatment strategy for these patients. It is im-
portant to understand more about the genetics and biol-
ogy of these CYLD-mutant tumors, which may point to
new treatment or prevention of these disfiguring tumors.
Further understanding of the role of CYLD in head and
neck epithelial biology may also identify mechanisms of
tumorigenesis and progression of head and neck
cancers, as well as other human malignancies.Additional file
Additional file 1: Figure S1. Graph showing the mutation
frequencies of CYLD gene in major cancer types. Data were extracted
from the cBioPortal database (www.cbioportal.org; dated 3rd August,
2016). The CYLD mutation frequencies of 15 most updated TCGA
Provisional cancer cohorts, and five other important cancer types
with CYLD mutation rates of >1–3 % rates were shown, with actual
number of mutated cases shown in this legend. Abbreviations:
Uterine (TCGA Provisional): Uterine Corpus Endometrial Carcinoma
13/248 cases (5.2 %), Lung squ (TCGA Provisional): Lung Squamous
Cell Carcinoma 8/177 cases (4.5 %), Stomach (TCGA Provisional):
Stomach Adenocarcinoma 15/395 cases (3.8 %), Lung adeno (TCGA
Provisional): Lung Adenocarcinoma 7/230 cases (3 %), Head & neck
(TCGA Provisional): Head and Neck Squamous Cell Carcinoma 15/512
cases (2.9 %), Cholangiocarcinoma (JHU, 2013): Intrahepatic
Cholangiocarcinoma 1/40 (2.5 %), Small Cell Lung (JHU, 2012): Small
Cell Lung Cancer 1/42 (2.4 %), Melanoma (TCGA Provisional): Skin
Cutaneous Melanoma 8/368 cases (2.2 %), Esophagus (TCGA
Provisional): Esophageal Carcinoma 4/185 cases (2.2 %), DLBC (TCGA
Provisional): Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 1/48
case (2.1 %), Colorectal (TCGA Provisional): Colorectal Adenocarcinoma
4/223 cases (1.8 %), Glioma (UCSF, 2014): Low-Grade Gliomas 1/61
(1.6 %), Thymoma (TCGA Provisional): Thymoma 2/123 cases (1.6 %),
chRCC (TCGA Provisional): Kidney Chromophobe 1/66 case (1.5 %),
MM (Broad, 2014): Multiple Myeloma 3/205 (1.5 %), Pancreas (TCGA
Provisional): Pancreatic Adenocarcinoma 2/150 cases (1.3 %), Uveal
melanoma (TCGA Provisional): Uveal melanoma 1/80 case (1.3 %),
GBM (TCGA, 2008): Glioblastoma 1/91 (1.1 %), Liver (TCGA Provisional):
Liver Hepatocellular Carcinoma 4/373 cases (1.1 %), Cervical (TCGA
Provisional): Cervical Squamous Cell Carcinoma & Endocervical
Adenocarcinoma 2/194 cases (1 %). (PPTX 77 kb)
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